Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

128.26 +0.14 (+0.11%)
Streaming Delayed Price Updated: 11:39 AM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
69 70 Next >
Infinity Pharmaceuticals Says Second Proxy Advisory Firm Recommends Shareholders To Approve Proposed Merger
Infinity Pharmaceuticals Inc (NASDAQ: INFI) announced further design features of its Phase 2 MARIO-8 study in Squamous Cell Cancer of the  
Via Benzinga
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
Read the latest report on NanoViricides here. 
Via Benzinga
Retirement Stocks: Here’s Where to Invest $1,000 Right Now
Retirement strategies focus on long-term potential and dividend management. These retirement stocks meet the mark if you have $1,000 today. 
Via InvestorPlace
Merck & Co Unusual Options Activity
Via Benzinga
2 Best Biotech Stocks to Buy in July
These are two of the largest pharmaceutical companies on the planet. 
Via The Motley Fool
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
Read the latest report on NanoViricides here. 
Via Benzinga
Merck & Co Unusual Options Activity For June 21
Via Benzinga
Is Merck Stock a Top Buy Right Now?
The drugmaker is still a work in progress. 
Via The Motley Fool
The 3 Best Dividend ETFs to Buy for July
If you feel some hesitation toward the economic recovery narrative, these best dividend ETFs should help sleep easier at night. 
Via InvestorPlace
Why Shares of Ventyx Biosciences Rose Monday
The company has several promising autoimmune therapies. 
Via The Motley Fool
Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still Buys
Both companies are facing significant patent cliffs, but they've been preparing for this moment. 
Via The Motley Fool
Here’s Why Boring Stocks Make Exciting Option Trades
Chasing volatility has its downsides. Sometimes it makes more sense to steer clear of it and instead look for less volatile stocks to trade options on. This also means you'll want to change your... 
Via Talk Markets
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Via Talk Markets
The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023
Investors looking to buy low and eventually sell high would be smart to take a position with one or more of these pharma stocks. 
Via InvestorPlace
This Sentiment Gauge Just Reached Its Most Optimistic Level Since Pre-Covid Days. Time to Buy Stocks?
Many stocks are trading at reasonable levels after declines last year. 
Via The Motley Fool
Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says
Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was... 
Via Benzinga
Merck, Ridgeback Withdraw COVID-19 Pill European Application Amid Regulatory Hurdles
Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics have reportedly withdrawn their COVID-19 pill application in the European Union (EU). 
Via Benzinga
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
Merck & Co Accused of Underplaying Mental Health Risks from Asthma and Allergy Drug Singulair
Initially, when released in 1998, Merck & Co Inc's (NYSE: MRK) asthma and allergy drug, Singulair, claimed side effects were mild and similar to a placebo, and the label stated that its distribution in... 
Via Benzinga
2 Low-Priced Stocks That Could Make You Richer
These two low-priced healthcare stocks could skyrocket within the next 12 months. 
Via The Motley Fool
Wall Street Says This Beaten-Down Stock May Climb Nearly 78%. Is That Too Optimistic?
Can former high-flyer Moderna soar again? 
Via The Motley Fool
MRK: Garner Income From This Pharma Giant
Merck & Co. has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, which seems right for a mature industry. 
Via Talk Markets
Dear SCHD ETF Fans, Mark Your Calendars for June 26
Fans of the Schwab US Dividend Equity ETF (SCHD) will want to keep an eye on the company when June 26 rolls around for a dividend payment. 
Via InvestorPlace
Pharmaceutical Lobbying Group Challenges Biden Administration Over Medicare Price Negotiations
The Pharmaceutical Research and Manufacturers of America (PhRMA), the National Infusion Center Association, and the Global Colon Cancer Association have filed a lawsuit against the Biden administration... 
Via Benzinga
Biotech And Healthcare Stocks Lagging
Healthcare is a laggard with XLV down YTD but UNH is still a core position. 
Via Talk Markets
Merck Says Keytruda Regimen Fails To Improve Event-Free Survival In Gastric Cancer Patients
Merck & Co Inc (NYSE: MRK) announced topline results from the Phase 3 KEYNOTE-585 trial of Keytruda (pembrolizumab) in combination with chemotherapy as a  
Via Benzinga
Got $5,000? Buy These 2 Stocks and Hold Them Until Retirement
Not every familiar name is a company you can comfortably tuck away in your portfolio for decades, but these two are. 
Via The Motley Fool
Merck's Keytruda Combo Therapy Hits Primary Goal In Patients With Rare Form Of Gastric Cancer
Merck & Co Inc (NYSE: MRK) announced topline data from the Phase 3 KEYNOTE-811 trial of Keytruda (pembrolizumab) plus trastuzumab and chemotherapy for human epidermal growth factor receptor 2... 
Via Benzinga
ChatGPT Portfolio Is Beating Most Funds: Is AI The Future Of Investing?
Via Benzinga
Why Are IO Biotech Shares Trading Lower Today
IO Biotech (NASDAQ: IOBT) randomized 225 patients in its global Phase 3 clinical trial for IO102-IO103, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in  
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
69 70 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.